CLAIMS

1. A conjugated compound comprising:
   a) a ST receptor binding moiety; and,
   b) an active moiety;
wherein said active moiety is a radiostable active agent.

2. The compound of claim 1 wherein said ST receptor binding moiety is a peptide.

3. The compound of claim 1 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof.

4. The compound of claim 1 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

5. The compound of claim 1 wherein said an active moiety is a therapeutic agent.

6. The compound of claim 1 wherein said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

7. The compound of claim 1 wherein:
   a) said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof;

b) said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

8. The compound of claim 1 wherein said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, *cis*-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, *Pseudomonas* exotoxin and diphtheria toxin.

9. The compound of claim 1 wherein:

a) said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54; and

b) said an active moiety is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, *cis*-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, *Pseudomonas* exotoxin and diphtheria toxin.

10. A pharmaceutical composition comprising:

a) a pharmaceutically acceptable carrier or diluent, and,

b) a conjugated compound according to claim 1.

11. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition according to claim 10.

12. A pharmaceutical composition comprising:

a) a pharmaceutically acceptable carrier or diluent, and,

b) conjugated compound comprising:

i) a ST receptor binding moiety; and,

ii) an active moiety;

wherein said active moiety is a radioactive agent and said conjugated compound is present in an amount effective for therapeutic or diagnostic use in a humans suffering from colorectal cancer.

13. The pharmaceutical composition of claim 12 wherein said active moiety is selected from the group consisting of: ^{47}Sc, ^{67}Cu, ^{90}Y, ^{109}Pd, ^{123}I, ^{125}I, ^{131}I, ^{186}Re, ^{188}Re, ^{199}Au, ^{211}At, ^{212}Pb, ^{212}B, ^{32}P and ^{33}P, ^{71}Ge, ^{77}As, ^{103}Pb, ^{105}Rh, ^{111}Ag, ^{119}Sb, ^{121}Sn, ^{131}Cs, ^{143}Pr, ^{161}Tb, ^{177}Lu, ^{191}Os, ^{193M}Pt and ^{197}Hg.

14. The pharmaceutical composition of claim 12 wherein said active moiety is selected from the group consisting of: ^{43}K, ^{52}Fe, ^{57}Co, ^{67}Cu, ^{67}Ga, ^{68}Ga, ^{77}Br, $^{81}Rb/^{81M}Kr$, ^{87M}Sr, ^{99M}Tc, ^{111}In, ^{113M}In, ^{123}I, ^{125}I, ^{127}Cs, ^{129}Cs, ^{131}I, ^{132}I, ^{197}Hg, ^{203}Pb and ^{206}Bi.

15. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is a peptide.

16. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof.

17. The pharmaceutical composition of claim 12 wherein said ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

18. The pharmaceutical composition of claim 12 wherein

said ST receptor binding moiety is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54; and

said active moiety is selected from the group consisting of ^{47}Sc, ^{67}Cu, ^{90}Y, ^{109}Pd, ^{123}I, ^{125}I, ^{131}I, ^{186}Re, ^{188}Re, ^{199}Au, ^{211}At, ^{212}Pb, ^{212}B, ^{32}P and ^{33}P, ^{71}Ge, ^{77}As, ^{103}Pb, ^{105}Rh, ^{111}Ag, ^{119}Sb, ^{121}Sn, ^{131}Cs, ^{143}Pr, ^{161}Tb, ^{177}Lu, ^{191}Os, ^{193M}Pt and ^{197}Hg.

19. The pharmaceutical composition of claim 12 wherein

said ST receptor binding moiety is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54; and

said active moiety is selected from the group consisting of ^{43}K, ^{52}Fe, ^{57}Co, ^{67}Cu, ^{67}Ga, ^{68}Ga, ^{77}Br, $^{81}Rb/^{81M}Kr$, ^{87M}Sr, ^{99M}Tc, ^{111}In, ^{113M}In, ^{123}I, ^{125}I, ^{127}Cs, ^{129}Cs, ^{131}I, ^{132}I, ^{197}Hg, ^{203}Pb and ^{206}Bi.

20. A method of radioimaging metastasized colorectal cancer cells comprising the steps of administering to an individual a pharmaceutical composition comprising:

a) a pharmaceutically acceptable carrier or diluent, and,

b) conjugated compound comprising:

i) a ST receptor binding moiety; and,

ii) an active moiety;

wherein said active moiety is a radioactive agent and said conjugated compound is present in an amount effective for diagnostic use in a humans suffering from colorectal cancer.

21. A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising:

a) a pharmaceutically acceptable carrier or diluent, and,

b) conjugated compound comprising:

i) a ST receptor binding moiety; and,

ii) an active moiety;

wherein said active moiety is a radiostable agent or radioactive agent and said conjugated compound is present in an amount effective for therapeutic or diagnostic use in a humans suffering from colorectal cancer.

22. A method of delivery a nucleic acid molecule to intestinal tract cells of an individual comprising the steps of administering to said individual a pharmaceutical composition comprising:

a) a pharmaceutically acceptable carrier or diluent, and,

b) a composition comprising:

i) a ST receptor ligand; and,

ii) a nucleic acid molecule.